Good evening :)
$
₹
Cytosorbents Crp

Cytosorbents Crp

CTSO

NASDAQ
Asset Logo

Cytosorbents Crp

CTSO

NASDAQ
$4.3617.26% (-0.91)
$
₹
$4.3617.26% (-0.91)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Medical Devices

Micro Cap

With a market cap of $16.6M the stock is ranked 5521

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

11.42
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-5.8
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

0
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

-48.94%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 1 analyst's reports

Buy
0 analyst
Hold
1 analyst
Sell
0 analyst

Price Upside

+801.33%

Earnings Growth

-1995.24%

Rev. Growth

+4.91%

See Detailed Forecast

Company Profile

Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform in the United States, Germany, and internationally. Its flagship product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses, bilirubin in liver failure, myoglobin in trauma and critical illnesses, and inflammatory mediators and blood thinners in cardiac surgery applications, as well as to remove antithrombotic drugs and inflammatory mediators in cardiothoracic surgery applications. The company also develops DrugSorb-ATR antithrombotic removal system, an investigational device to reduce the severity of perioperative bleeding in high-risk surgery due to blood thinning drugs; ECOS-300CY to reduce cytokines and other inflammatory mediators when used in an ex vivo organ perfusion system; VetResQ, a broad-spectrum blood purification adsorber for the treatment of septic shock, toxic shock syndrome, toxin-mediated diseases, pancreatitis, trauma, liver failure, heat stroke, and lung injury in animals; and PuriFi, an advanced hemoperfusion pump for blood purification therapies. In addition, it develops HemoDefend-BGA, a blood purification technology platform to reduce anti-A and anti-B antibodies in plasma and whole blood. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform in the United States, Germany, and internationally. Its flagship product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses, bilirubin in liver failure, myoglobin in trauma and critical illnesses, and inflammatory mediators and blood thinners in cardiac surgery applications, as well as to remove antithrombotic drugs and inflammatory mediators in cardiothoracic surgery applications. The company also develops DrugSorb-ATR antithrombotic removal system, an investigational device to reduce the severity of perioperative bleeding in high-risk surgery due to blood thinning drugs; ECOS-300CY to reduce cytokines and other inflammatory mediators when used in an ex vivo organ perfusion system; VetResQ, a broad-spectrum blood purification adsorber for the treatment of septic shock, toxic shock syndrome, toxin-mediated diseases, pancreatitis, trauma, liver failure, heat stroke, and lung injury in animals; and PuriFi, an advanced hemoperfusion pump for blood purification therapies. In addition, it develops HemoDefend-BGA, a blood purification technology platform to reduce anti-A and anti-B antibodies in plasma and whole blood. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
Abbott Laboratories
ABT
Abbott Laboratories
P/E Ratio
38.55
38.55
1Y Return
18.86%
18.86%
Buy Reco %
85.71
85.71
Danaher Corporation
DHR
Danaher Corporation
P/E Ratio
38.16
38.16
1Y Return
3.48%
3.48%
Buy Reco %
83.33
83.33
Intuitive Surgical Inc
ISRG
Intuitive Surgical Inc
P/E Ratio
54.69
54.69
1Y Return
17.95%
17.95%
Buy Reco %
76.47
76.47
Medtronic PLC
MDT
Medtronic PLC
P/E Ratio
23.44
23.44
1Y Return
1.27%
1.27%
Buy Reco %
66.66
66.66
Stryker Corporation
SYK
Stryker Corporation
P/E Ratio
31.82
31.82
1Y Return
19.81%
19.81%
Buy Reco %
79.31
79.31
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Higher price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies 801.33% growth, versus a trailing 3-year CAGR of -47.82%.

2026
Current$5.27Baseline
Analyst Target - 1 year
Target$47.5+801.33%

All values in $

202220232024202520262027$16.62$28.50$40.37Target+801.33%
2026
Current$5.27Baseline
Analyst Target - 1 year
Target$47.5+801.33%

All values in $

Revenue Forecast

Revenue Forecast

Higher revenue growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The next fiscal year's mean estimate implies 4.91% growth, versus a trailing 3-year CAGR of 2.23%.

2025
Current$37.06Baseline
Forecast for Dec 2026
High$39.61+6.88%
Average$38.88+4.91%
Low$38.15+2.93%

All values in $ Million

20212022202320242025202640.1034.6831.0835.5937.06Low+2.93%Average+4.91%High+6.88%
2025
Current$37.06Baseline
Forecast for Dec 2026
High$39.61+6.88%
Average$38.88+4.91%
Low$38.15+2.93%

All values in $ Million

Earnings Per Share Forecast

Earnings Per Share Forecast

2025
Current$-0.21Baseline
Forecast for Dec 2026
High$-4.4-1995.24%
Average$-4.4-1995.24%
Low$-4.4-1995.24%

All values in $

202120222023202420252026-0.57-0.75-0.65-0.42-0.21Low-1995.24%Average-1995.24%High-1995.24%
2025
Current$-0.21Baseline
Forecast for Dec 2026
High$-4.4-1995.24%
Average$-4.4-1995.24%
Low$-4.4-1995.24%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

9.4
-3.1
9.2
-5.4
8.8
-5.1
9.6
-4.4
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue8.988.848.619.158.729.619.489.238.869.63
Net Income-6.08-4.29-2.33-7.88-1.471.94-3.17-5.49-5.12-4.41
Net Profit Margin-67.73%-48.56%-27.10%-86.15%-16.93%20.24%-33.42%-59.52%-57.86%-45.85%
See CostsAll values in $ Million

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareMedical Devices

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Cytosorbents Crp -11.420
Abbott Laboratories38.553.572.12
Danaher Corporation38.162.951.32
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare CTSO with any stock or ETF
Compare CTSO with any stock or ETF
Comparing from
CTSO
ABT
DHR
Loading...

Frequently asked questions

  1. Cytosorbents Crp (CTSO) share price today is $4.36 as of October 26, 2026 at 11:07 PM IST. The stock touched a day high of $5.59 and a day low of $4.27.

  2. Cytosorbents Crp stock trades on NASDAQ under the ticker symbol CTSO.

  3. Cytosorbents Crp's market capitalization is $16.6M as of October 26, 2026 at 11:07 PM IST.

  4. Cytosorbents Crp's price-to-earnings (P/E) ratio is N/A as of October 26, 2026.

  5. Cytosorbents Crp's price-to-book (P/B) ratio is 11.42 as of October 26, 2026.

  6. Yes, You can buy Cytosorbents Crp shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Cytosorbents Crp shares in three steps: 1. Search Cytosorbents Crp on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Cytosorbents Crp trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Cytosorbents Crp (CTSO) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 2.2935 shares at the current price of $4.36.

Loading...